AI Bolus Priming for Type 1 Diabetes

(AIDANET AI Trial)

This trial explores a new method for managing Type 1 Diabetes by using artificial intelligence (AI) to adjust insulin doses based on meal patterns. The treatment, called AIDANET AI, connects via a smartphone app to an insulin pump and glucose monitor, aiming to regulate blood sugar levels more effectively. Participants will test different system setups for several weeks to evaluate its effectiveness in managing diabetes. This trial suits adults who have had Type 1 Diabetes for at least a year and are already using an automated insulin delivery system. As an unphased trial, it offers the chance to explore innovative diabetes management technology and contribute to advancing future treatment options.

The trial requires that you do not start any new non-insulin glucose-lowering medications during the study. If you are currently taking such medications, you must have been on a stable dose for at least the past month. Additionally, you cannot use certain medications like SGLT-2 inhibitors or steroids.

Research has shown that the AIDANET system can safely assist people with Type 1 Diabetes in managing their blood sugar levels. Various studies have demonstrated that the AIDANET system improves blood sugar control, helping maintain levels within a healthy range. Importantly, these studies also indicate that most users find the system easy to use.

For example, one study found that the AIDANET system significantly improved blood sugar levels in 34 people with Type 1 Diabetes. Another study showed that the system can automatically adjust insulin delivery by analyzing blood sugar data in real-time, reducing the time blood sugar levels are outside the target range. So far, trials have reported no major side effects, suggesting that the system is safe to use.

Researchers are excited about the AI Bolus Priming for Type 1 Diabetes because it introduces the AIDANET AI system, which offers a unique approach to managing blood sugar levels. Unlike standard treatments that rely heavily on human input, such as traditional insulin pumps or multiple daily injections, AIDANET AI uses artificial intelligence to automate insulin delivery decisions. This technology could potentially enhance precision and ease the burden of constant monitoring for patients. By adapting to individual needs in real-time, AIDANET AI may improve blood sugar control more effectively than current methods, offering a significant advancement in diabetes management.

Research has shown that AI-based systems like AIDANET AI can significantly assist people with type 1 diabetes in managing their blood sugar levels. These systems monitor blood sugar in real-time and automatically adjust insulin delivery, allowing individuals to maintain their blood sugar within the optimal range more consistently. In this trial, participants in Group A will progress from their home HCL system to AIDANET and then to AIDANET AI, while Group B will start with AIDANET AI, transition to AIDANET, and finally return to their home HCL systems. A recent study demonstrated that the AIDANET system managed insulin levels as effectively as expert doctors. Various studies have proven AI-driven insulin delivery systems to be safe and effective, offering promising results for improved diabetes management.²⁴⁶⁷⁸